Novartis Venture Fund
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Novartis Venture Fund was established in 1996, and is a well known VC. The primary office of this VC is located in Basel. The fund is located in Switzerland, Europe. Novartis Venture Fund is a CVC is a part of a larger organization.
The fund's activity peaked in 2009. Besides, in 2019 the fund was active. When Novartis Venture Fund invests, the average start-up valuation is 10-50 millions dollars. The fund performance shows that this VC achieves 7 percentage points more exits in comparison to other VCs. Novartis Venture Fund participates, on average, in 4 percentage points less than the average amount of lead investments in other funds. The highest number of exits from this fund were in 2014. The fund typically enters into 7-12 deals annually. Typical investments for this fund are deals in the range of 10 - 50 millions dollars.
The fund typically invests in rounds with 5-6 participants. Aside from Novartis Venture Fund, start-ups are often funded by SV Health Investors, Apple Tree Partners, ARCH Venture Partners and 108 other funds. Other VCs who often invest in the same rounds are Versant Ventures, Venture Investors, Truffle Capital, the total number of co-investors is 151. In subsequent rounds, the fund is usually joined by Sofinnova Investments, Astellas Venture Management, Venture Investors, as well as 132 other investors.
The fund was created by Argeris Karabelas. The overall number of key employees in the fund's team is 5.
The fund has an exact preference in the amount of founders of companies in its portfolio. When a start-up has 5+ founders, the probability of closing the deal is low. Among their most successful investment fields, we have identified Medical Device, Life Science. Also, because of its portfolio diversification tendency, we can highlight 11 more industries for this fund. Moreover, a start-up needs to be 6-10 years old to get investment from this fund. Alios BioPharma, Merus, Catalyst Biosciences are amongst the various portfolio companies of this fund. The country of its foundation and the country of the most frequent investments for the fund doesn't coincide - United States. In addition to this location, the fund participated in 11 other locations.
Group Appearance [how often fund is operating separately from groups with shared interest]
100.0% of cases
Investments per Year [average amount of rounds in which fund participates each year]
Follow-on Index [how often fund is ready to support its portfolio startup at next rounds]
33.5% of cases
Average Multiplicator [the average ratio of the last valuation of portfolio startups to their total amount of financing raised]
Average Portfolio Company
Exit Age [the average age of portfolio startups at which they go public or become acquired]
Success / Strategy Similarity
Index [the matching between fund's investment strategy and its proved successes in the form of portfolio startups high valuations]
0.75 out of 1
Number of Unicorns [amount of portfolio companies, which were valuated at more then $1B]
Funds Investing in Following
By posting comments on our website you confirm and acknowledge that:
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.